GLP-1 Agonists Show No Increased Suicide Risk in Large Cohort

Navigating the Neuropsychiatric Safety of Incretin Mimetics

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a cornerstone of metabolic therapy, with meta-analyses of 137 randomized controlled trials involving 39,845 patients showing that 48.6% of individuals achieve hemoglobin A1c targets below 7% [1]. Beyond glycemic control, these agents offer significant cardiovascular benefits, including a mean systolic blood pressure reduction of 3.37 mmHg (95% CI -3.95 to -2.80) and decreased hospitalizations for heart failure [2, 3]. However, regulatory warnings regarding potential risks of suicide or suicide attempts have complicated their clinical use [4], even as some data suggest liraglutide 1.8 mg daily may improve symptoms of anhedonia (the inability to experience pleasure) and depression [5]. A new nationwide analysis now clarifies these neuropsychiatric safety concerns, providing clinicians with the data necessary to manage high-risk populations with greater confidence.

Comparative Safety Across Antidiabetic Classes

Regulatory scrutiny from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) has necessitated a rigorous evaluation of the psychiatric safety of GLP-1 RAs. To address this, researchers employed a new-user, active comparator cohort design, a robust epidemiological method that compares patients starting a new medication against those starting a different drug for the same condition. This design is critical for clinicians to understand because it minimizes confounding by indication, which occurs when the underlying disease, rather than the drug itself, influences the observed outcome. The study analyzed two large populations: a cohort of 83,464 GLP-1 RA users versus 78,366 sodium-glucose cotransporter-2 (SGLT-2) inhibitor users, and a second cohort of 108,322 GLP-1 RA users versus 55,411 dipeptidyl peptidase-4 (DPP-4) inhibitor users. When compared to SGLT-2 inhibitors, GLP-1 RA initiation showed no significant difference in the risk of suicide or suicide attempts, yielding a hazard ratio of 0.93 (95% CI: 0.57 to 1.52), where a hazard ratio is a measure of how often an event happens in one group compared to another over time.

Intra-Patient Analysis and Long-Term Outcomes

Comparative analysis against other incretin-based therapies further supports the safety profile of GLP-1 RAs in psychiatric contexts. In the comparison with DPP-4 inhibitors, GLP-1 RA users actually demonstrated a lower risk of suicide or suicide attempts, with a hazard ratio of 0.58 (95% CI: 0.37 to 0.91). To validate these findings, the researchers also utilized a self-controlled case series (a statistical technique where each patient acts as their own control, effectively neutralizing fixed individual factors like genetics or baseline mental health history). This intra-patient analysis compared event rates before and after starting the medication across three distinct time periods. The results indicated that GLP-1 RA use was associated with a lower incidence rate ratio (IRR) of suicide or suicide attempts one year after initiation (IRR: 0.45; 95% CI: 0.10 to 0.50). This trend persisted into the second year of treatment, with a reduced IRR maintained between 13 and 24 months compared to the pretreatment period, suggesting that the psychiatric safety of these medications is maintained throughout the first two years of clinical use.

Clinical Implications for Metabolic Management

These findings provide substantial clinical reassurance for physicians prescribing GLP-1 RAs for type 2 diabetes or obesity management. By integrating data from both the active comparator cohorts and the self-controlled case series, the study offers a comprehensive view of the psychiatric safety landscape. The lack of an increased risk across multiple comparisons and timeframes suggests that the concerns raised by regulatory agencies may not translate into a measurable clinical hazard in general practice. For the practicing clinician, this means that GLP-1 RA therapy does not appear to necessitate specialized psychiatric surveillance beyond the standard of care. Instead, the focus can remain on the established metabolic and cardiovascular benefits of these agents, as the evidence indicates they do not correlate with an elevation in suicidal behavior or self-harm events. This study confirms that GLP-1 RA use was not associated with an increased incidence of suicide or suicide attempts in either the active comparator new-user design or the self-controlled case series design.

References

1. Esposito K, Chiodini P, Ceriello A, Giugliano D. A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39,845 patients.. Acta diabetologica. 2014. doi:10.1007/s00592-012-0370-9

2. Wong HJ, Toh KZ, Teo Y, et al. Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials. Journal of Hypertension. 2024. doi:10.1097/HJH.0000000000003903

3. McGowan B, Ciudin A, Baker JL, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nature Medicine. 2025. doi:10.1038/s41591-025-03978-z

4. Valentino K, Teopiz KM, Cheung WWL, et al. The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review. Journal of Psychiatric Research. 2025. doi:10.1016/j.jpsychires.2025.02.008

5. Meshkat S, Luciano CD, Swiderski A, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.. Brain and behavior. 2025. doi:10.1002/brb3.70661